Pharmafile Logo
Pharmafocus logo
Advanced Search

Pompe disease

Showing 7 posts of 7 posts found.

genes

Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate

May 10, 2024
Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics

Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …

News

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

October 6, 2023
Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …

News

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

News

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

May 3, 2023
Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …

News
sanofi_logo_vertical_2011_4colors

Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment

March 4, 2016
Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

News

Genzyme plans new Belgium facility

January 25, 2011
Manufacturing and Production Belgium, Genzyme, Lumizyme, Myozyme, Pompe disease, Sanofi-Aventis, alglucosidase alfa

US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …

News

FDA approves Genzyme’s Lumizyme

May 27, 2010
Sales and Marketing Genzyme, Lumizyme, Myozyme, Pompe disease

US biotech Genzyme is celebrating FDA approval of its late-onset treatment for Pompe disease Lumizyme. The green light to market …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026